F.D.A. Panel Votes Against MDMA-Assisted Therapy for PTSD

The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.

The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.

Read more

Psychedelics for Soldiers with Trauma

From TIME magazine:

Research suggests that the psychedelic drug MDMA, an empathogenic stimulant also known as Molly or ecstasy, can spark changes in the brain that induce a childlike state of neuroplasticity and help forge new neural connections.

(It could well be approved for PTSD by the U.S. Food and Drugs Administration in August after two advanced stage trials showed significant benefits.)

Researchers are also studying other psychedelics as well, like the powerful drug ibogaine.

Read more

Psychedelics, Alcoholism and PTSD

This study evaluated prospective associations of ibogaine and 5-MeO-DMT treatment for risky alcohol use and post-traumatic stress disorder (PTSD) symptoms among United States (US) Special Operations Forces Veterans (SOFV).

Future clinical trials should determine whether psychedelic-assisted therapy holds promise for individuals with complex trauma and alcohol misuse who have not been successfully treated with traditional interventions.

Read more